APD418APD418 is a potentially first-in-class, investigational, β3-adrenergic receptor (AdrR) antagonist and cardiac myotrope for decompensated heart failure. APD418 is a selective antagonist designed to improve cardiac contractility with minimal effect on heart rate and blood pressure. Inhibition of β3-AdrR–mediated myofilament repression may provide a cardiomyocyte-specific target to enhance cardiac contractile performance. Arena discovered and developed this investigational drug internally.
Clinical TrialAPD418 is an investigational drug and is not currently approved for use by any health authority.
ACUTE HEART FAILURE